Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene.
10.7534/j.issn.1009-2137.2020.01.021
- Author:
Peng CUI
1
;
Dong XU
2
;
Tian XING
1
;
Guo-Hua REN
1
;
Shang-Min MA
1
Author Information
1. Department of Blood Rheumatism and Immunity, Zibo First Hospital, Zibo 255200, Shandong Province, China.
2. Department of Blood Rheumatism and Immunity, Zibo First Hospital, Zibo 255200, Shandong Province, China,E-mail :wyxudong@163.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):125-129
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze relation of ASXL2 gene mutation with the clinical characteristics, prognosis and C-KIT gene mutation in acute myeloid leukemia (AML) patients with AML1-ETO fusion gene.
METHODS:The clinical data of 63 primary AML patients with AML1-ETO fusion gene were collected and retrospectively analyzed. The mutation of ASXL2 gene was directly sequenced by PCR. The clinical characteristics, C-KIT mutation rate and prognosis were compared between the patients with ASXL2 gene mutation (group A) and non-mutation (group B).
RESULTS:Among 63 patients, 8 (12.70%) cases of ASXL2 mutation gene was detected. Hemoglobin level in peripheral blood of patients in group A was significantly lower than that in group B (P＜0.01). There was no significant difference in sex, ages proportion of bone marrow blasts, lymph node enlargement, peripheral blood leukocytes count and platelets between the two groups (P＞0.05). The infiltration of central nervous system, liver and spleen was not found in both groups. The expression of CD33 in group A was significantly lower than that in group B (P＜0.05), but the results of other immunophenotype analysis were not significantly different between the two groups (P＞0.05). The remission rate and median survival time were not significantly different between two groups (P＞0.05). The detection rate of C-KIT gene mutation were not significantly different between group A and group B (P＞0.05).
CONCLUSION:Among AML patients with AML1-ETO fusion gene, ASXL2 gene mutation accounts for a certain ratio, and the peripheral blood hemoglobin concentration and CD33 expression in these patients are often low. At the same time, ASXL2 gene mutation may not be closely related with C-KIT gene mutation.
